Boehringer Ingelheim International Gmbh

Evotec International Gmbh

Joerg P Hehn

Andreas Blum

Dieter Wiedenmayer

Dirk Gottschling

Armin Heckel

Georg Dahmann

Stefan Peters

Martin Thomas Fleck

Florian Paul Christian Binder

Jens Willwacher

Elke Langkopf

Joerg Kley

Annekatrin Charlotte Heimann

Uta Friederike Lessel

Bernhard Schmid

Oliver Hucke

Matthias Eckhardt

Christoph Hoenke

Dieter Wolfgang Hamprecht

Sara Frattini

Holger Wagner

Thorsten Lehmann-Lintz

Cédrickx Godbout

Iain Lingard

Andreas Gollner

Bernd Wellenzohn

Remko Alexander Bakker

Thorsten Lehmann

This invention related to substituted tetrazoles and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.

Substituted tetrazoles as TRPA1 inhibitors

The invention relates to new pyridinyl sulfonamide derivatives of the formula wherein R, A and n are as defined herein, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof

This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.

Thienopyrimidones

Disclosed are heteroarylcarboxamides of formula (I), and pharmaceutically acceptable salts thereof, wherein A, T, R, Rand Rare as defined herein. Also disclosed are methods of using these compounds for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.

Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors

The present invention relates to compounds of general formula I, wherein the group R, X and Y are defined as in claim, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. 

Azabenzimidazole derivatives as agonists of the AMP-activated protein kinase

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I), wherein Ar, Rand Rare as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders. 

Sulfoximine substituted quinazolines for pharmaceutical compositions

The present invention relates to compounds of formula (I), or the tautomers or pharmacologically acceptable acid addition salts thereof, wherein R, R, R, R, X, and Z have one of the meanings as defined in the specification, to the use of compounds of formula (I) as a medicament, to pharmaceutical composition comprising at least one compound of formula (I), as well as to medicament combinations containing one or more compounds of formula (I).

Substituted benzimidazolium compounds useful in the treatment of respiratory diseases

The invention relates to new pyridinyl derivatives of the formula wherein Rand A are as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Pyridinyl derivatives, pharmaceutical compositions and uses thereof

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, Rand Rare as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, Rand Rare as defined herein, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

Growing community of inventors

Biberach an der Riss, Germany

Joerg P Hehn